|
1
|
Schmidt F and Efferth T: Tumor
heterogeneity, single-cell sequencing, and drug resistance.
Pharmaceuticals (Basel). 9. pp. 332016, View Article : Google Scholar
|
|
2
|
Zukotynski K, Jadvar H, Capala J and Fahey
F: Targeted radionuclide therapy: Practical applications and future
prospects. Biomark Cancer. 8(Suppl 2): 35–38. 2016.PubMed/NCBI
|
|
3
|
Otte A: Neuroendocrine tumors: Peptide
receptors radionuclide therapy (PRRT). Hell J Nucl Med.
19:1822016.PubMed/NCBI
|
|
4
|
Dash A, Knapp FF and Pillai MR: Targeted
radionuclide therapy - an overview. Curr Radiopharm. 6:152–180.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sneath RJ and Mangham DC: The normal
structure and function of CD44 and its role in neoplasia. Mol
Pathol. 51:191–200. 1998. View Article : Google Scholar
|
|
6
|
Todaro M, Gaggianesi M, Catalano V,
Benfante A, Iovino F, Biffoni M, Apuzzo T, Sperduti I, Volpe S,
Cocorullo G, et al: CD44v6 is a marker of constitutive and
reprogrammed cancer stem cells driving colon cancer metastasis.
Cell Stem Cell. 14:342–356. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shi J, Zhou Z, Di W and Li N: Correlation
of CD44v6 expression with ovarian cancer progression and
recurrence. BMC Cancer. 13:1822013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Tjhay F, Motohara T, Tayama S, Narantuya
D, Fujimoto K, Guo J, Sakaguchi I, Honda R, Tashiro H and Katabuchi
H: CD44 variant 6 is correlated with peritoneal dissemination and
poor prognosis in patients with advanced epithelial ovarian cancer.
Cancer Sci. 106:1421–1428. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ni J, Cozzi PJ, Hao JL, Beretov J, Chang
L, Duan W, Shigdar S, Delprado WJ, Graham PH, Bucci J, et al: CD44
variant 6 is associated with prostate cancer metastasis and
chemo-/radioresistance. Prostate. 74:602–617. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wu XJ, Li XD, Zhang H, Zhang X, Ning ZH,
Yin YM and Tian Y: Clinical significance of CD44s, CD44v3 and
CD44v6 in breast cancer. J Int Med Res. 43:173–179. 2015.
View Article : Google Scholar
|
|
11
|
Afify A, Durbin-Johnson B, Virdi A and
Jess H: The expression of CD44v6 in colon: From normal to
malignant. Ann Diagn Pathol. 20:19–23. 2016. View Article : Google Scholar
|
|
12
|
Fox SB, Fawcett J, Jackson DG, Collins I,
Gatter KC, Harris AL, Gearing A and Simmons DL: Normal human
tissues, in addition to some tumors, express multiple different
CD44 isoforms. Cancer Res. 54:4539–4546. 1994.PubMed/NCBI
|
|
13
|
Heider KH, Mulder JW, Ostermann E, Susani
S, Patzelt E, Pals ST and Adolf GR: Splice variants of the cell
surface glycoprotein CD44 associated with metastatic tumour cells
are expressed in normal tissues of humans and cynomolgus monkeys.
Eur J Cancer. 31A:2385–2391. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lv L, Liu HG, Dong SY, Yang F, Wang QX,
Guo GL, Pan YF and Zhang XH: Upregulation of CD44v6 contributes to
acquired chemoresistance via the modulation of autophagy in colon
cancer SW480 cells. Tumour Biol. 37:8811–8824. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Bellerby R, Smith C, Kyme S, Gee J,
Günthert U, Green A, Rakha E, Barrett-Lee P and Hiscox S:
Overexpression of specific CD44 isoforms is associated with
aggressive cell features in acquired endocrine resistance. Front
Oncol. 6:1452016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Saito S, Okabe H, Watanabe M, Ishimoto T,
Iwatsuki M, Baba Y, Tanaka Y, Kurashige J, Miyamoto Y and Baba H:
CD44v6 expression is related to mesenchymal phenotype and poor
prognosis in patients with colorectal cancer. Oncol Rep.
29:1570–1578. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Omran OM and Ata HS: CD44s and CD44v6 in
diagnosis and prognosis of human bladder cancer. Ultrastruct
Pathol. 36:145–152. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shiozaki M, Ishiguro H, Kuwabara Y, Kimura
M, Mitsui A, Naganawa Y, Shibata T, Fujii Y and Takeyama H:
Expression of CD44v6 is an independent prognostic factor for poor
survival in patients with esophageal squamous cell carcinoma. Oncol
Lett. 2:429–434. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Motohara T, Fujimoto K, Tayama S,
Narantuya D, Sakaguchi I, Tashiro H and Katabuchi H: CD44 variant 6
as a predictive biomarker for distant metastasis in patients with
epithelial ovarian cancer. Obstet Gynecol. 127:1003–1011. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang Q, Liu Y, Huang Y, Huang D, Li Y, Wu
J and Duan M: Expression of COX-2, CD44v6 and CD147 and
relationship with invasion and lymph node metastasis in
hypopharyngeal squamous cell carcinoma. PLoS One. 8:e710482013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu HG, Lv L and Shen H: Intratumoral
heterogeneity of CD44v6 in rectal cancer. Clin Transl Oncol.
19:425–431. 2017. View Article : Google Scholar
|
|
22
|
Spiegelberg D, Kuku G, Selvaraju R and
Nestor M: Characterization of CD44 variant expression in head and
neck squamous cell carcinomas. Tumour Biol. 35:2053–2062. 2014.
View Article : Google Scholar :
|
|
23
|
Spiegelberg D and Nilvebrant J:
CD44v6-targeted imaging of head and neck squamous cell carcinoma:
Antibody-based approaches. Contrast Media Mol Imaging.
2017:27095472017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Haylock AK, Spiegelberg D, Mortensen AC,
Selvaraju RK, Nilvebrant J, Eriksson O, Tolmachev V and Nestor MV:
Evaluation of a novel type of imaging probe based on a recombinant
bivalent mini-antibody construct for detection of CD44v6-expressing
squamous cell carcinoma. Int J Oncol. 48:461–470. 2016. View Article : Google Scholar :
|
|
25
|
Spiegelberg D, Mortensen AC, Selvaraju RK,
Eriksson O, Stenerlöw B and Nestor M: Molecular imaging of EGFR and
CD44v6 for prediction and response monitoring of HSP90 inhibition
in an in vivo squamous cell carcinoma model. Eur J Nucl Med Mol
Imaging. 43:974–982. 2016. View Article : Google Scholar :
|
|
26
|
Börjesson PK, Postema EJ, Roos JC, Colnot
DR, Marres HA, van Schie MH, Stehle G, de Bree R, Snow GB, Oyen WJ,
et al: Phase I therapy study with (186)Re-labeled humanized
monoclonal antibody BIWA 4 (bivatuzumab) in patients with head and
neck squamous cell carcinoma. Clin Cancer Res. 9:3961S–3972S.
2003.PubMed/NCBI
|
|
27
|
Jødal L: Beta emitters and radiation
protection. Acta Oncol. 48:308–313. 2009. View Article : Google Scholar
|
|
28
|
Mujammami M, Hier MP, Payne RJ, Rochon L
and Tamilia M: Long-term outcomes of patients with papillary
thyroid cancer undergoing remnant ablation with 30 milliCuries
radioiodine. Thyroid. 26:951–958. 2016. View Article : Google Scholar
|
|
29
|
Makis W, McCann K and McEwan AJ: Orbital
metastases of neuroendocrine tumors treated with
177Lu-DOTATATE PRRT or 131I-MIBG therapies. Clin Nucl
Med. 41:137–141. 2016. View Article : Google Scholar
|
|
30
|
Bergsma H, Konijnenberg MW, van der Zwan
WA, Kam BL, Teunissen JJ, Kooij PP, Mauff KA, Krenning EP and
Kwekkeboom DJ: Nephrotoxicity after PRRT with
(177)Lu-DOTA-octreotate. Eur J Nucl Med Mol Imaging. 43:1802–1811.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
NuDat 2 [Internet]. Cited Mar 7, 2017.
Available from: http://www.nndc.bnl.gov/nudat2/.
|
|
32
|
Hindié E, Zanotti-Fregonara P, Quinto MA,
Morgat C and Champion C: Dose deposits from 90Y,
177Lu, 111In, and 161Tb in
micrometastases of various sizes: Implications for
radiopharma-ceutical therapy. J Nucl Med. 57:759–764. 2016.
View Article : Google Scholar
|
|
33
|
Wang G, Wu Z, Wang Y, Li X, Zhang G and
Hou J: Therapy to target renal cell carcinoma using 131I-labeled
B7-H3 monoclonal antibody. Oncotarget. 7:24888–24898.
2016.PubMed/NCBI
|
|
34
|
Long B, Yang M, Yang Z, Yi H and Li L:
Assessment of radio-iodine therapy efficacy for treatment of
differentiated thyroid cancer patients with pulmonary metastasis
undetected by chest computed tomography. Oncol Lett. 11:965–968.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Steidl S, Ratsch O, Brocks B, Dürr M and
Thomassen-Wolf E: In vitro affinity maturation of human GM-CSF
antibodies by targeted CDR-diversification. Mol Immunol.
46:135–144. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ostendorp R, Frisch C and Urban M:
Generation, engineering and production of human antibodies using
hucal. Antibodies. Subramanian G: Springer; US: pp. 13–52. 2004,
View Article : Google Scholar
|
|
37
|
Cho MS, Yee H and Chan S: Establishment of
a human somatic hybrid cell line for recombinant protein
production. J Biomed Sci. 9:631–638. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wolff J and Chaikoff IL: Plasma inorganic
iodide as a homeo-static regulator of thyroid function. J Biol
Chem. 174:555–564. 1948.PubMed/NCBI
|
|
39
|
Eng PH, Cardona GR, Fang SL, Previti M,
Alex S, Carrasco N, Chin WW and Braverman LE: Escape from the acute
Wolff-Chaikoff effect is associated with a decrease in thyroid
sodium/iodide symporter messenger ribonucleic acid and protein.
Endocrinology. 140:3404–3410. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Tolmachev V, Malmberg J, Estrada S,
Eriksson O and Orlova A: Development of a 124I-labeled version of
the anti-PSMA monoclonal antibody capromab for immunoPET staging of
prostate cancer: Aspects of labeling chemistry and biodistribution.
Int J Oncol. 44:1998–2008. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sehlin D, Fang XT, Meier SR, Jansson M and
Syvänen S: Pharmacokinetics, biodistribution and brain retention of
a bispecific antibody-based PET radioligand for imaging of
amyloid-β. Sci Rep. 7:172542017. View Article : Google Scholar
|
|
42
|
Haylock A-K, Spiegelberg D, Nilvebrant J,
Sandström K and Nestor M: In vivo characterization of the novel
CD44v6-targeting Fab fragment AbD15179 for molecular imaging of
squamous cell carcinoma: A dual-isotope study. EJNMMI Res.
4:112014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Steffen AC, Wikman M, Tolmachev V, Adams
GP, Nilsson FY, Ståhl S and Carlsson J: In vitro characterization
of a bivalent anti-HER-2 affibody with potential for
radionuclide-based diagnostics. Cancer Biother Radiopharm.
20:239–248. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brown BA, Comeau RD, Jones PL, Liberatore
FA, Neacy WP, Sands H and Gallagher BM: Pharmacokinetics of the
monoclonal antibody B72.3 and its fragments labeled with either
125I or 111In. Cancer Res. 47:1149–1154.
1987.PubMed/NCBI
|
|
45
|
Ahl PL, Bhatia SK, Meers P, Roberts P,
Stevens R, Dause R, Perkins WR and Janoff AS: Enhancement of the in
vivo circulation lifetime of L-alpha-distearoylphosphatidylcholine
liposomes: Importance of liposomal aggregation versus complement
opsonization. Biochim Biophys Acta. 1329:370–382. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Holechek MJ: Glomerular filtration: An
overview. Nephrol Nurs J. 30:285–290; quiz 291-292. 2003.PubMed/NCBI
|
|
47
|
Blau M: Letter: Radiation dosimetry of
131-I-19-iodocholesterol: The pitfalls of using tissue
concentration data. J Nucl Med. 16:247–249. 1975.PubMed/NCBI
|
